

ORIGINAL

Role of circulating soluble chemokines in septic shock[☆]

R. de Pablo^{a,b,*}, J. Monserrat^b, A. Prieto^b, M. Álvarez-Mon^{b,c}

^a Unidad de Cuidados Intensivos, Hospital Universitario Príncipe de Asturias, Madrid, Spain

^b Laboratorio de Enfermedades del Sistema Inmune y Oncología, Unidad asociada al Centro Nacional de Biotecnología, Departamento de Medicina, Universidad de Alcalá, Madrid, Spain

^c Servicio de Enfermedades del Sistema Inmune y Oncología, Hospital Universitario Príncipe de Asturias, Madrid, Spain

Received 29 July 2012; accepted 24 September 2012

KEYWORDS

Chemokines;
Septic shock;
Acute respiratory
distress syndrome;
Acute renal failure;
Coagulopathy;
Biomarkers

Abstract

Purpose: Chemokines are a large superfamily of small proteins that not only function in leukocyte trafficking, but are also necessary for linkage between innate and adaptive immunity. Little is known about their role in septic shock. We hypothesized that serum levels of the most important chemokines are related to organ failure, disease severity and outcome.

Design: A prospective observational study was carried out.

Setting: Surgical-clinical Intensive Care Unit.

Patients: Ninety-two patients diagnosed with septic shock using international criteria. Forty patients were excluded due to acquired immunity disturbances. Samples from 36 healthy controls were also analyzed.

Interventions: None.

Results: In 46% of the patients who suffered acute respiratory distress syndrome (ARDS), IL-8 levels were higher than in patients without ARDS (499.9 ± 194.1 vs 190.8 ± 91.7 pg/ml; $p=0.039$). This molecule was also higher in 36% of the patients with sepsis-induced acute renal failure (ARF) (453.3 ± 181.6 vs 201.3 ± 95.9 pg/ml; $p=0.049$). Coagulopathy was found in 19% of the septic shock patients with elevated serum IL-8 levels (635.8 ± 292.3 vs 218.7 ± 87.0 pg/ml; $p=0.010$), elevated MIP-1 α (91.4 ± 27.3 vs 58.8 ± 11.1 pg/ml; $p=0.044$), and low circulating RANTES levels (8162.2 ± 6321.0 vs 18781.8 ± 11.1 pg/ml; $p=0.027$). No significant differences were found between survivors and non-survivors at any time of follow-up.

Conclusions: Upon admission to the ICU, IL-8 is a reliable biomarker of sepsis-induced AFR, ARDS and coagulopathy. Altered circulating MIP-1 α and RANTES levels are also found in patients with septic shock and coagulopathy. However, chemokines do not appear to be good biomarkers of mortality in septic shock.

© 2012 Elsevier España, S.L. and SEMICYUC. All rights reserved.

[☆] Please cite this article as: de Pablo R, Monserrat J, Prieto A, Álvarez-Mon M. Papel de las quimioquinas solubles circulantes en el shock séptico. Med Intensiva. 2013;37:510–518.

* Corresponding author.

E-mail address: raul.depablo@uah.es (R. de Pablo).

PALABRAS CLAVE

Quimioquinas;
Shock séptico;
Síndrome de distrés
respiratorio agudo;
Fracaso renal agudo;
Coagulopatía;
Biomarcadores

Papel de las quimioquinas solubles circulantes en el shock séptico**Resumen**

Objetivo: Las quimioquinas son una gran familia de pequeños péptidos que tienen una participación clave no solo en el control del tráfico de los leucocitos, sino también se ha visto que son necesarios en las interacciones entre la inmunidad innata y adaptativa. El papel de estas moléculas es poco conocido en el seno del shock séptico. Nuestra hipótesis es que los niveles séricos de las principales quimioquinas tienen relación con los diferentes fallos orgánicos y con el pronóstico de los pacientes con shock séptico.

Diseño: Estudio prospectivo y observacional.

Ámbito: Unidad de Cuidados Intensivos médico-quirúrgica.

Pacientes: Noventa y dos pacientes cumplieron criterios internacionales de shock séptico con demostración de una infección, de los que se excluyeron 40 por presentar diferentes alteraciones inmunitarias adquiridas. Treinta y seis voluntarios sanos sirvieron de grupo control.

Intervenciones: Ninguna.

Resultados: El 46% de los pacientes presentaron síndrome de distrés respiratorio agudo (SDRA) y en ellos los niveles séricos de IL-8 se encontraban elevados ($499,9 \pm 194,1$ vs. $190,8 \pm 91,7$ pg/ml; $p=0,039$). Esta molécula también estaba elevada en el 36% de los pacientes con shock séptico que tenían fracaso renal agudo (FRA) ($453,3 \pm 181,6$ vs. $201,3 \pm 95,9$ pg/ml; $p=0,049$). El 19% de los pacientes presentaron coagulopatía y en ellos se observó una elevación de los niveles de IL-8 ($635,8 \pm 292,3$ vs. $218,7 \pm 87,0$ pg/ml; $p=0,010$), de MIP-1 α ($91,4 \pm 27,3$ vs. $58,8 \pm 11,1$ pg/ml; $p=0,044$) y niveles bajos de RANTES ($8162,2 \pm 6321,0$ vs. $18781,8 \pm 11,1$ pg/ml; $p=0,027$). No encontramos diferencias significativas en los niveles séricos de quimioquinas estudiadas en pacientes con shock séptico entre los supervivientes y los que fallecieron.

Conclusiones: Al ingreso en la UCI, la IL-8 es un buen biomarcador de FRA y de SDRA, así como de coagulopatía en pacientes con shock séptico. MIP-1 α y RANTES también presentan niveles séricos alterados en la coagulopatía asociada a la sepsis. A pesar de esto, las quimioquinas no parecen ser buenos marcadores pronósticos en estos pacientes.

© 2012 Elsevier España, S.L. y SEMICYUC. Todos los derechos reservados.

Introduction

Multiorgan failure is the main cause of death in patients with sepsis.¹ The prognosis of multiorgan dysfunction syndrome (MODS) is conditioned to the number of failed organs, the severity of failure, and its duration in time. In a study published by Knaus et al., the mortality rate was 22% among patients with single organ failure lasting less than 24 h, but increased to 42% when the condition persisted for 7 days. In turn, the mortality rate was found to be 80% in the case of three or more failed organs with a duration of less than 24 h, and reached 100% when the condition persisted for more than four days.²

Although severity scores have been developed to characterize the degree of multiorgan dysfunction and predict mortality among patients with sepsis, understanding the pathophysiology of MODS represents an ongoing challenge.³ The development of MODS is a consequence of excessive activation of the inflammatory response. To date, however, the treatments that have attempted to counter this exaggerated systemic inflammatory response have failed.⁴ Furthermore, most patients who survive the initial aggression of sepsis die days or weeks later as a result of multiorgan failure and in a situation of immunosuppression.³

At cellular level, a number of mechanisms contribute to the development of MODS, including microvascular thrombosis, neutrophil-induced damage, bacterial translocation,

cytokine release, endothelial dysfunction, cell apoptosis, etc.⁵ The chemokines constitute a large family of cytokines that stimulate the movement of leukocytes and regulate their migration from the bloodstream toward the tissues. They are regarded as proinflammatory cytokines, since they induce the production and release of histamine, enzymes and defensins. However, in contrast to other cytokines, the chemokines do not induce other cytokines or produce fever or acute phase reactants. Furthermore, chemokines in large circulating concentrations exert desensitizing effects and can suppress local inflammation.⁶

Nuclear factor- κ B (NF- κ B) plays a key role in the pathophysiology of sepsis and septic shock. An increase in its activity has been associated with a higher mortality rate and a poorer prognosis.⁷ NF- κ B mediates the transcription of a range of genes encoding for inflammatory molecules such as cytokines, adhesion molecules, enzymes, immune receptors, acute phase reactants and chemokines—including interleukin-8 (IL-8), macrophage inflammatory protein 1- α (MIP-1 α), type 1 monocyte chemoattractant protein (MCP-1) and RANTES (regulated on activation, normal T cell expressed and secreted) protein. The role of these chemokines when soluble in plasma in the development of organ dysfunction in patients with sepsis has not been well established to date.

The present study postulates that the plasma levels of these circulating chemokines are increased in patients with

septic shock, and that this in turn contributes to the development of organ dysfunction and patient mortality.

Patients and methods

On a retrospective basis and covering a period of approximately 36 months, we included those patients over 18 years of age with severe sepsis admitted to the Intensive Care Unit (ICU). Severe sepsis was diagnosed based on the presence of sepsis plus the failure of some organ, hypoperfusion or hypotension, in compliance with the criteria of the consensus conference of the American College of Chest Physicians/Society of Critical Care Medicine⁸ (Table 1). The demonstration of infection was also considered essential, using microbiological techniques (gram staining and/or culture), radiological techniques, or direct visualization of the infection site.

The following exclusion criteria were established:

- a) Primary or acquired immunodeficiency of any kind
- b) Previous immunosuppressive or immune modulating treatment
- c) Uncontrolled or actively treated neoplastic disease
- d) Active autoimmune or allergic disorders
- e) The need for extrarenal filtration techniques capable of affecting clearance of the different inflammatory mediators
- f) Administration of experimental therapy

We analyzed peripheral blood samples from 36 health volunteers (controls) with an age and gender distribution similar to that of the patients included in the study, in order to prevent the demographic characteristics from interfering with the interpretation of the results. The study protocol was approved by the Clinical Research Ethics Committee. The relatives of the patients and healthy controls gave informed consent to the experimental protocol.

All the patients received conventional treatment. None received activated protein C, and individuals needing hydrocortisone due to refractory hypotension were excluded from the study.

Blood samples were collected through the arterial catheter in tubes without anticoagulant in the first 12 h after admission to the ICU (baseline sample), 48 h after admission, and after 7, 14 and 28 days. An additional 10 ml of blood was extracted and allowed to clot at room temperature, followed by serum separation by centrifugation at $600 \times g$ during 20 min. The supernatants were collected, filtered and divided into aliquots that were stored frozen at -70°C until use.

After thawing of the supernatants to room temperature, sandwich ELISA testing was carried out. The results obtained were measured with the Multititer Plus[®] enzymeimmunoassay reader (Tiertek Multiscan Plus, Flow Laboratories, United Kingdom), and were compared with a standard curve obtained from known concentrations of each cytokine, supplied by the manufacturer.

The analysis of the different standard curves and subsequent interpolations were carried out with the Delta Soft II[®] version 4.1 software (Biometallies, Inc., USA) on a Macintosh[®] computer.

Table 1 Criteria of sepsis, septic shock and of each type of organ failure.

<p>Criteria of sepsis: 2 or more of the following 4 criteria must be met</p> <p><i>Fever or hypothermia: temperature $>38^\circ\text{C}$ or $<36^\circ\text{C}$</i></p> <p><i>Tachycardia: heart rate >90 bpm</i></p> <p><i>Hyperventilation: respiratory frequency >20 rpm or partial CO_2 pressure <32 mmHg, or minute-volume >10 l/min</i></p> <p><i>Leukocytosis $>12,000$ cells/mm³ or leukopenia <4000 cells/mm³, or $>10\%$ young cell forms (band cells, etc.)</i></p>
<p>Criteria of septic shock: patients with sepsis associated to hypotension, hypoperfusion or the need for circulatory support measures</p> <p><i>Hypotension: systolic blood pressure <90 mmHg or a drop >40 mmHg with respect to baseline in patients with a history of arterial hypertension</i></p> <p><i>Hypoperfusion: presence of lactic acidosis, oliguria <0.5 ml/kg body weight and hour and/or altered consciousness</i></p> <p><i>Circulatory support: need for positive balance >2000 ml/day without any other justifying cause, or need for the administration of vasoactive drugs</i></p>
<p>Definition of organ failure: the following criteria must be maintained for over 24 h</p> <p><i>Cardiovascular: presence of one or more of the following</i></p> <p>Heart rate: <55 bpm</p> <p>Mean blood pressure: <50 mmHg</p> <p>Tachycardia or ventricular fibrillation</p> <p>Need for vasoactive drugs</p> <p><i>Respiratory: criteria of acute respiratory distress syndrome</i></p> <p>$\text{PaO}_2/\text{FiO}_2$: <200 mmHg</p> <p>Bilateral infiltration on chest X-rays</p> <p>Pulmonary capillary pressure: <19 mmHg</p> <p>Justifying acute process</p> <p><i>Renal: presence of at least one of the following</i></p> <p>Diuresis: <160 ml/8 h or <480 ml in 24 h</p> <p>Blood urea nitrogen (BUN): >100 mg/dl</p> <p>Plasma creatinine: >3.5 mg/dl</p> <p><i>Hematological: presence of at least one of the following</i></p> <p>Leukopenia: $<1000/\text{mm}^3$</p> <p>Thrombocytopenia: $<20,000/\text{mm}^3$</p> <p>Hematocrit: $<20\%$</p> <p><i>Neurological: Glasgow coma score: <7</i></p> <p><i>Hepatic:</i></p> <p>INR: >1.5</p> <p>Bilirubin: >6 mg/dl</p>

The determinations of the concentrations of the different cytokines were made using the commercial formulations with a supernatant quantitation sensitivity of 25 pg/ml for IL-8 (Diacclone, USA), 5 pg/ml for MCP-1 (R&D System, Minneapolis, USA), 10 pg/ml for MIP-1 α (R&D System, Minneapolis, USA), and 10 pg/ml for RANTES (R&D System, Minneapolis, USA).

In relation to the statistical study, we first examined the nature of the distributions using the Shapiro–Wilk normality




Figure 1 Flow of the studied and evaluated subjects.

test. When the data obtained showed a normal distribution, comparisons of means were established using the Student *t*-test. In the case of data with a non-normal distribution, comparisons were made using the nonparametric Mann–Whitney *U*-test. Comparison of data from one same group at different time intervals was carried out with the Friedman test, while correlations between the different variables were established using the Pearson correlation coefficient.

The results of the experimental studies are presented as the mean and standard error of the mean (sem). In all cases significance levels of under 5% were considered ($p < 0.05$). The SPSS version 11.0 statistical package (SPSS Inc., Chicago, IL 60606, USA) was used throughout.

Results

Fig. 1 shows the flow of the 128 individuals studied, including 52 patients (all with septic shock), 40 excluded subjects and 36 healthy controls. The demographic characteristics of the patients are summarized in **Table 2**.

Table 2 Demographic data of the patients.

Age (years)	61.6 ± 3.6
Males/females	36/16
Clinical/surgical	24/28
APACHE II	24.26 ± 1.41
MODS	7.66 ± 0.69
δ-MODS	2.69 ± 0.49
SOFA	8.89 ± 0.74
δ-SOFA	2.11 ± 0.63

The results are expressed as mean ± standard error of the mean. APACHE II (Acute Physiology and Chronic Health Evaluation),⁴⁴ MODS (Multiple Organ Dysfunction Score),⁴⁵ MODS,⁴⁶ SOFA (Sequential Organ Failure Assessment),⁴⁷ and SOFA⁴⁸ are severity scores.

Chemokine levels with respect to the control group

The serum levels of the studied soluble chemokines (IL-8, MCP-1, MIP-1 α and RANTES) showed special and individualized behavior in each case.

As can be seen in panel A of **Fig. 2**, IL-8 maintained extraordinarily elevated levels throughout the evolution of sepsis.

The concentration of MCP-1 was very high in the first phase and then gradually decreased to normalization by day 28 (panel B of **Fig. 2**).

There were no significant differences between the levels of MIP-1 α among the controls and in the patients at any timepoint (panel C of **Fig. 2**).

On the other hand, as can be seen in panel D of **Fig. 2**, the RANTES levels were below those of the controls at all timepoints of the disease.

Prognostic value of the soluble chemokine levels

The mortality rate among the patients was 34.6%. In the patients with septic shock, we found no significant differences in serum chemokine levels between the survivors and those who died (**Table 3**).

Correlation between the chemokine levels and failure of the different organs

Among the 6 organ system failures considered (cardiovascular, acute respiratory distress syndrome [ARDS], acute renal failure [ARF], coagulopathy, liver failure and neurological failure), the incidence of liver failure ($n = 3$) and of neurological failure ($n = 2$) was so low that no conclusions can be drawn from the data obtained. On the other hand, all the patients met criteria of cardiovascular failure and were classified as presenting septic shock. The patients with ARDS upon admission totaled 46%, while the incidence of ARF was 36%, and that of coagulopathy 19%.

Analysis of the chemokine levels at the time of admission to the ICU and in relation to the different types of organ failure showed the serum levels of IL-8 to be significantly higher in the patients admitted with ARDS than in those without ARDS, and also in those with ARF compared with the patients who did not develop ARF (**Fig. 3**). In relation to the rest of the chemokines (MCP-1, MIP-1 α and RANTES), no significant differences were observed at the time of admission in those with ARDS or in those with ARF (**Figs. 4–6**).

The IL-8 and MIP-1 α levels in the patients with coagulopathy were higher than in those without coagulopathy upon admission (**Figs. 3 and 5**). Significant differences were also observed in the levels of RANTES, with lower concentrations upon admission to the ICU in patients with coagulopathy than in those without (**Fig. 6**).

Discussion

In the present study we found chemokines to be involved in the development of different types of organ damage. Interleukin-8 is increased in patients with septic shock, and these levels are good markers of respiratory, renal and




Figure 2 Soluble chemokine levels in patients with septic shock. Panel A: levels of IL-8 in pg/ml versus time in days. Panel B: levels of MCP-1 in pg/ml versus time in days. Panel C: levels of MIP-1α in pg/ml versus time in days. Panel D: levels of RANTES in pg/ml versus time in days. The values are expressed as the mean and standard error of the mean.

hematological failure. Two other chemokines are also implicated in the case of patients with coagulopathy, namely MIP-1α and RANTES.

Hack et al.⁹ were the first to report that 89% of the patients with sepsis had high IL-8 levels upon admission and during follow-up over 60 h, though in contrast to our own findings, the levels decreased in the course of follow-up. The physiopathological basis for this finding is the fact that endotoxin, IL-1β, and especially TNF-α are the main stimuli for IL-8 production and release. Measurement of the serum concentrations of IL-8 has been used to predict which patients have bacteremia in a group of subjects reporting to the

emergency service due to systemic inflammatory response syndrome (SIRS),¹⁰ though other authors prefer to use the procalcitonin levels for this purpose.¹¹

A range of soluble molecules have been evaluated as potential prognostic markers in patients with sepsis.¹²⁻¹⁵ In this context, the prognostic usefulness of IL-8 concentration has been described by several authors.^{16,17}

Recently, different studies using commercial multitests and simultaneously determining 17 molecules in patients with sepsis have found IL-8 to be one of the best prognostic biomarkers in patients of this kind.¹⁸⁻²⁰ We and other investigators have not obtained such results.²¹ Possibly, the reason for this discrepancy is that our patients, in contrast




Figure 3 Levels of IL-8 in patients with septic shock upon admission to the ICU. C: controls; ARDS: acute respiratory distress syndrome; ARF: acute renal failure; DIC: disseminated intravascular coagulation. The criteria are specified in Table 1.




Figure 4 Levels of MCP-1 in patients with septic shock upon admission to the ICU. C: controls; ARDS: acute respiratory distress syndrome; ARF: acute renal failure; DIC: disseminated intravascular coagulation. The criteria are specified in Table 1.

Table 3 Chemokine levels in the control group and at each evaluative timepoint of sepsis.

	Baseline				3 d		7 d		14 d		28 d	
	Non-survivors (n = 18)	Survivors (n = 34)	Non-survivors (n = 13)	Survivors (n = 34)	Non-survivors (n = 11)	Survivors (n = 34)	Non-survivors (n = 11)	Survivors (n = 34)	Non-survivors (n = 11)	Survivors (n = 34)	Non-survivors (n = 11)	Survivors (n = 34)
IL-8 (pg/ml)	2.02 ± 0.37	265.7 ± 113.3 ^a	103.4 ± 37.5 ^a	170.0 ± 127.4 ^a	187.2 ± 162.2 ^a	70.5 ± 18.1 ^a	178.5 ± 135.5 ^a	21.96 ± 3.18 ^a	178.5 ± 135.5 ^a	70.5 ± 18.1 ^a	178.5 ± 135.5 ^a	21.96 ± 3.18 ^a
MCP1 (pg/ml)	204.9 ± 59.7	3.020.8 ± 670.7 ^a	1.839.9 ± 732.3 ^a	917.3 ± 218.3 ^a	1.192.4 ± 268.5 ^a	640.7 ± 151.4	568.1 ± 143.1 ^a	378.9 ± 113.9	568.1 ± 143.1 ^a	640.7 ± 151.4	568.1 ± 143.1 ^a	378.9 ± 113.9
MIP-1α (pg/ml)	38.4 ± 2.9	67.7 ± 12.9	56.2 ± 17.7	38.4 ± 7.3	34.4 ± 3.1	44.5 ± 10.0	46.7 ± 7.6	26.2 ± 6.7	46.7 ± 7.6	44.5 ± 10.0	46.7 ± 7.6	26.2 ± 6.7
RANTES (pg/ml)	58.000 ± 3.204	20.714 ± 3.624 ^a	6.914 ± 4.919 ^a	16.900 ± 6.008 ^a	8.371 ± 8.338 ^a	29.279 ± 5.866 ^a	33.162 ± 6.323 ^a	28.924 ± 4.452 ^a	33.162 ± 6.323 ^a	29.279 ± 5.866 ^a	33.162 ± 6.323 ^a	28.924 ± 4.452 ^a

The results are expressed as mean ± standard error of the mean.
^a p < 0.05 between each timepoint and the controls. There were no significant differences between survivors and non-survivors.




Figure 5 Levels of MIP-1α in patients with septic shock upon admission to the ICU. C: controls; ARDS: acute respiratory distress syndrome; ARF: acute renal failure; DIC: disseminated intravascular coagulation. The criteria are specified in Table 1.

to those of the other studies, were in a more serious condition, with higher APACHE II scores and practically all in a state of shock—this making it more difficult to find differences in the levels of IL-8. In effect, in the studies published by Halstensen et al.²² and Damas,¹⁶ patients with shock had higher levels than patients with sepsis but no cardiovascular failure.

Interleukin-8 has been identified as the main chemotactic factor of polymorphonuclear neutrophils in the lungs.²³ Boutten et al.²⁴ demonstrated a correlation between the neutrophil count and the concentration of IL-8 in bronchoalveolar lavage (BAL) obtained from different lung segments in 17 patients with unilateral pneumonia. We recorded higher IL-8 concentrations in patients with ARDS upon admission to the ICU than in those without ARDS. Some studies have analyzed this point and confirm our findings.^{16,25} It has been shown that the IL-8 levels in bronchoalveolar lavage are increased in patients with ARDS,^{26,27} and are moreover correlated to chronification of the disease.²⁸

We observed significant differences in the levels of IL-8 among patients with ARF upon admission to the ICU as a consequence of sepsis. Fujishima et al.¹⁷ correlated the blood IL-8 levels to the development of ARF and mortality. The study published by Ahlström et al.²⁹ likewise confirms




Figure 6 Levels of RANTES in patients with septic shock upon admission to the ICU. C: controls; ARDS: acute respiratory distress syndrome; ARF: acute renal failure; DIC: disseminated intravascular coagulation. The criteria are specified in Table 1.

our results. Interleukin-8 is probably implicated in the pathophysiology of ARF in septic patients, though there are no conclusive experimental data in this respect. We therefore cannot discard the possibility that IL-8 elevation is simply a problem of renal clearance and accumulation of the molecule in situations of renal failure. In our study the IL-8 levels were higher in patients with coagulopathy at the onset of sepsis. The previously mentioned studies by Damas¹⁶ and Fujishima¹⁷ in septic patients confirm our data. Interleukin-8 is implicated in the induction of intravascular coagulation associated to endotoxin.³⁰ It promotes the activation of coagulation, particularly through mediation by CD14+ monocytes.³¹ Thrombin in turn stimulates the production of IL-8 by monocytes and endothelial cells.³¹ An increase in blood IL-8 has also been described in coagulopathy associated to acute promyelocytic leukemia.³²

Type 1 monocyte chemoattractant protein (MCP-1) is a CC chemokine that acts as a mediator in monocyte and T lymphocyte tissue infiltration in a broad range of inflammatory diseases. In our study we recorded elevated MCP-1 levels upon admission compared with the control group, and these levels were seen to subsequently decrease progressively, with normalization after 28 days. These same results have been obtained by other authors.^{33,34} However, some investigators³⁵ have only recorded elevated MCP-1 levels in the bronchoalveolar lavage of patients with sepsis, but not in serum. In this sense, we did not record elevated concentrations in patients with ARDS or any other organ failure upon admission. On the other hand, MCP-1 is admittedly regarded as a second signal and would be implicated in monocyte infiltration; consequently, at the time of admission it might not be possible to appreciate the clinical relevance which this mediator probably has at a later stage in time.

We found no differences in the serum MCP-1 levels during the first week of sepsis between the patients who died and those who survived. Similar results have been obtained by other authors.³⁴

Macrophage inflammatory protein 1- α (MIP-1 α) is fundamentally a macrophage chemotactic protein, although it has also been associated with chemotactic and proadhesive effects upon other cell types. MIP-1 α also exerts modulating effects upon the production of cytokines, and is an endogenous pyrogen. Although experimentally MIP-1 α appears after the administration of lipopolysaccharides both *in vitro*³⁶ and *in vivo*,^{34,37} the results obtained on examining the serum levels in patients with severe sepsis were very notorious. In effect, we observed normal levels throughout the evolution of the disease, regardless of the prognosis. These same findings have been described by other groups.^{17,33–35,38}

All authors appear to agree that the MIP-1 α levels have no prognostic value or relation to the development of multiorgan failure.^{17,38} However, in our study we did observe differences in the levels of MIP-1 α among the patients with coagulopathy upon admission to the ICU versus those without coagulopathy. The only study we have found in this line is the work published by Fujishima et al.,¹⁷ and although a tendency toward increased levels of MIP-1 α was noted in the patients with coagulopathy, statistical significance was not reached.

The RANTES (regulated on activation, normal T cell expressed and secreted) protein is a CC chemokine produced by a series of cell types including platelets, lymphocytes

and epithelial cells, in response to pyrogenic signals such as endotoxin, bacterial infections and TNF- α .³⁹ Its main biological function is the trafficking and activation of both inflammatory and non-inflammatory cells.⁴⁰ Cavaillon et al.⁴¹ reported that the levels of RANTES in sepsis are inversely proportional to the APACHE II score; the authors thus deduced that RANTES is lower among the patients who do not survive. Møller et al.³³ demonstrated that patients with fulminant meningococemia had lesser RANTES concentrations than patients with other less serious meningococcal infections.

We also observed extraordinarily low RANTES levels compared with the healthy controls. However, we did not find significant differences in the levels between the survivors and those patients who died. The only form of organ failure in which there were significantly lower concentrations in the patients was the presence of coagulopathy upon admission in the ICU versus those without coagulopathy. This result is difficult to interpret. It is known that bacteria can stimulate the release of RANTES,³⁹ and that the administration of 4 ng/kg of endotoxin to 8 healthy volunteers resulted in a drop in RANTES levels.⁴² On the other hand, we also know that platelets are the principal source of RANTES.⁴³ Platelets express CD40 at surface level, which interacts with the CD154 receptor of activated T lymphocytes, inducing the release of RANTES stored in the platelets.⁴³

During the inflammatory response, RANTES is released into the intravascular compartment and rapidly binds to the endothelial surface, thereby giving rise to the recruitment and retention of leukocytes—including T cells.⁴⁰ This is where the interpretation difficulty lies: is the decrease in RANTES observed in coagulopathy attributable to depletion of the molecule upon binding to the vascular endothelium, or is it a consequence of a drop in the RANTES reservoir, i.e., the platelets? In hematological patients, Ellis et al.⁴⁰ found that in subjects with fever, RANTES concentration is related to the presence of thrombocytopenia. We posteriorly studied the correlation between the levels of RANTES and the platelet counts in blood among patients with severe sepsis during the first day of admission to the ICU. This nonparametric association, studied by means of the Spearman test, yielded a correlation of 0.546, with $p = 0.007$. We therefore cannot rule out the possibility that this decrease in RANTES levels among patients with coagulopathy is simply an expression of the thrombocytopenia found in these individuals.

In conclusion, in this study we have demonstrated the participation of chemokines IL-8, MIP-1 α and RANTES in coagulopathy associated to septic shock, as well as the usefulness of IL-8 as a biomarker of respiratory and renal failure. Nevertheless, these molecules appear to lack prognostic value in patients with septic shock.

Financial support

This study has been financed in part by the Community of Madrid, S-BIO-0189/2006, and by the *Fondo de Investigación Sanitaria*, PI-08-1890.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

The authors thank the medical and nursing team of the ICU of Príncipe de Asturias University Hospital for their collaboration in this study.

References

- Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med*. 2006;34:344–53.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. *Ann Surg*. 1985;202:685–93.
- Hotchkiss RS, Opal S. Immunotherapy for sepsis – a new approach against an ancient foe. *N Engl J Med*. 2010;363:87–9.
- Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. *Am Surg*. 2012;78:1–8.
- McConnell KW, Coopersmith CM. Organ failure avoidance and mitigation strategies in surgery. *Surg Clin North Am*. 2012;92:307–19.
- Krakauer T, Vilcek J, Oppenheim JJ. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF β , and others. In: Paul W, editor. *Fundamental immunology*. 5th ed. Philadelphia: LWW.com; 2003. p. 775–811.
- Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. *Am J Physiol Lung Cell Mol Physiol*. 2006;290:L622–45.
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest*. 1992;101:1644–55.
- Hack CE, Hart M, van Schijndel RJ, Eerenberg AJ, Nuijens JH, Thijs LG, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. *Infect Immun*. 1992;60:2835–42.
- Lin KJ, Lin J, Hanasawa K, Tani T, Kodama M. Interleukin-8 as a predictor of the severity of bacteremia and infectious disease. *Shock*. 2000;14:95–100.
- Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med*. 2001;164:396–402.
- De Pablo Sánchez R, Monserrat Sanz J, Prieto Martín A, Reyes Martín E, Álvarez de Mon Soto M, Sánchez García M. Balance entre citocinas pro y antiinflamatorias en estados sépticos. *Med Intensiva*. 2005;29:151–8.
- De Pablo R, Monserrat J, Reyes E, Diaz-Martin D, Rodriguez Zapata M, Carballo F, et al. Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. *J Intensive Care Med*. 2011;26:125–32.
- Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. *Curr Med Chem*. 2008;15:581–7.
- Suberviola B, Castellanos-Ortega A, González-Castro A, García-Astudillo LA, Fernández-Miret B. Prognostic value of procalcitonin, C-reactive protein and leukocytes in septic shock. *Med Intensiva*. 2012;36:177–84.
- Damas P, Canivet JL, de Groote D, Vrindts Y, Albert A, Franchimont P, et al. Sepsis and serum cytokine concentrations. *Crit Care Med*. 1997;25:405–12.
- Fujishima S, Sasaki J, Shinozawa Y, Takuma K, Kimura H, Suzuki M, et al. Serum MIP-1 alpha and IL-8 in septic patients. *Intensive Care Med*. 1996;22:1169–75.
- Andaluz-Ojeda D, Bobillo F, Iglesias V, Almansa R, Rico L, Gandía F, et al. A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis. *Cytokine*. 2012;57:332–6.
- Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. *Crit Care*. 2007;11:R49.
- Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, et al. Multiplex cytokine profiling in patients with sepsis. *APMIS*. 2011;119:155–63.
- Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. *Clin Chem Lab Med*. 1999;37:363–8.
- Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. *J Infect Dis*. 1993;167:471–5.
- Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. *Chest*. 2001;119:419S–25S.
- Boutten A, Dehoux MS, Seta N, Ostinelli J, Venembre P, Crestani B, et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. *Am J Respir Crit Care Med*. 1996;153:336–42.
- Chollet-Martin S, Jourdain B, Gibert C, Elbim C, Chastre J, Gougerot-Pocidal MA. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. *Am J Respir Crit Care Med*. 1996;154:594–601.
- Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet*. 1993;341:643–7.
- Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR, et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. *Am Rev Respir Dis*. 1992;146:427–32.
- Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. *Am Rev Respir Dis*. 1990;142:1250–7.
- Ahlström A, Hynninen M, Tallgren M, Kuusela P, Valtonen M, Orko R, et al. Predictive value of interleukins 6, 8 and 10, and low HLA-DR expression in acute renal failure. *Clin Nephrol*. 2004;61:103–10.
- Yang G, Li MZ, Zhang YP. Effects of injectio reduqing on plasma IL-8 and nitric oxide levels in rabbits with endotoxin induced disseminated intravascular coagulation. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 1996;16:417–20.
- Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. *J Immunol*. 1998;160:5130–5.
- Zeng H, Zhang X, Tao R. Expression of interleukin-8 and its receptor in acute promyelocytic leukemia under all-trans retinoic acid treatment. *Zhonghua Xue Ye Xue Za Zhi*. 1998;19:346–9.
- Møller AS, Bjerre A, Brusletto B, Joø GB, Brandtzaeg P, Kierulf P. Chemokine patterns in meningococcal disease. *J Infect Dis*. 2005;191:768–75.
- Olszyna DP, Prins JM, Dekkers PE, de Jonge E, Speelman P, van Deventer SJ, et al. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. *J Clin Immunol*. 1999;19:399–405.
- Mathiak G, Neville LF, Grass G, Boehm SA, Luebke T, Herzmann T, et al. Chemokines and interleukin-18 are up-regulated in bronchoalveolar lavage fluid but not in serum of septic surgical ICU patients. *Shock*. 2001;15:176–80.

36. Focà A, Berlinghieri MC, Barreca GS, Placanica PM, Diana R, Liberto MC, et al. Kinetics of IL-8, MIP-1 alpha, TNF, alpha, IL-1 beta, IL-1ra and IL-10 in human whole blood samples triggered by smooth and rough LPS. *New Microbiol.* 1998;21:123–30.
37. O'Grady NP, Tropea M, Preas 2nd HL, Reda D, Vandivier RW, Banks SM, et al. Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. *J Infect Dis.* 1999;179:136–41.
38. Knapp S, Thalhammer F, Locker GJ, Laczika K, Hollenstein U, Frass M, et al. Prognostic value of MIP-1 alpha, TGF-beta 2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis. *Clin Immunol Immunopathol.* 1998;87:139–44.
39. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. *J Neurochem.* 2002;82:1311–29.
40. Ellis M, al-Ramadi B, Hedström U, Frampton C, Alizadeh H, Kristensen J. Significance of the CC chemokine RANTES in patients with haematological malignancy: results from a prospective observational study. *Br J Haematol.* 2005;128:482–9.
41. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sepsis. *Scand J Infect Dis.* 2003;35:535–44.
42. Schinkel S, Schinkel C, Pollard V, Garofallo R, Heberle H, Reisner P, et al. Effects of endotoxin on serum chemokines in man. *Eur J Med Res.* 2005;10:76–80.
43. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. *J Immunol.* 2004;172:2011–5.
44. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med.* 1985;13:818–29.
45. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med.* 1995;23:1638–52.
46. Jacobs S, Zuleika M, Mphansa T. The Multiple Organ Dysfunction Score as a descriptor of patient outcome in septic shock compared with two other scoring systems. *Crit Care Med.* 1999;27:741–4.
47. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Crit Care Med.* 1998;26:1793–800.
48. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. *Intensive Care Med.* 1999;25:686–96.